Almirall and Certest Biotec announce research collaboration and licensing agreement

Barcelona and San Mateo de Gállego (Zaragoza), Spain.

Almirall, S.A. (ALM) and Certest Biotec, S.L., through its pharmaceutical division Certest Pharma, today announced a strategic research collaboration and licensing agreement. Through the collaboration, the parties will jointly discover and clinically develop novel treatments for rare dermatologic diseases and recurrent cutaneous conditions.

The collaboration combines Certest’s integrated mRNA and Lipid Nanoparticle Platform with Almirall’s expertise in medical dermatology research and clinical development.

“The collaboration with Certest Biotec is aligned with Almirall’s innovation strategy and supports our commitment to advancing a differentiated pipeline and developing novel therapies in medical dermatology that address unmet patient needs,” said Karl Ziegelbauer, Chief Scientific Officer at Almirall.

“This collaboration marks an important milestone for Certest and further validates the strength of our integrated mRNA and lipid nanoparticle platform,” said Nelson Fernandes, CEO of Certest. “Partnering with Almirall allows us to apply our technology to indications with significant unmet medical needs while reinforcing our commitment to enabling the next generation of RNA-based medicines.”